China’s focus on first or best-in-class oncology drugs and innovative R&D will help it to secure further licensing deals in ...

US-based private investment company SK Capital Partners’ affiliate is to invest in Swixx BioPharma to support its growth and ...

Akeega’s is now FDA indicated for mCSPC and mCRPC, widening the drug’s future market potential across the prostate cancer ...

Entasis’ Nuzolvence and GSK’s Blujepa are the first antibiotic approvals in gonorrhoea in over 30 years in the US.

The US Food and Drug Administration (FDA) has granted approval for Acadia Pharmaceuticals’ Daybue Stix (trofinetide).

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Sobi has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics for $950m.

Propelled by a flurry of dealmaking late in the year, 2025 M&A ended on a strong note, with high activity expected to ...

The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.

This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.

The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint. American ...

Golcadomide, a first-in-class, oral CELMoD (cereblon E3 ligase modulator), has shown compelling activity as a monotherapy and ...